18 June 2014
ValiRx Plc
("ValiRx" or "the Company")
Re: Launch of New Corporate Website & New Office Address
ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce the launch of its newly designed corporate website and to advise on the Company's new office address.
The re-developed site has an enhanced and modern design and contains information about the Company that includes details on its five current programmes, which seek to detect and effectively treat a range of cancers. The new corporate website can be viewed at www.valirx.com.
The Company also advises that it has moved offices to better accommodate its growing team. The Company's new office address is: 3rd Floor,
16 Upper Woburn Place,
London,
WC1H 0BS.
- ENDS -
For more information, please contact:
ValiRx plc |
Tel: +44 (0) 20 3008 4416 |
Dr Satu Vainikka |
www.valirx.com |
|
|
Cairn Financial Advisers LLP (Nominated Adviser) |
Tel: +44 (0) 20 7148 7900 |
Liam Murray / Avi Robinson |
|
|
|
Daniel Stewart & Company Plc (Broker) |
Tel: +44 (0) 20 7776 6550 |
David Hart |
|
Peckwater PR |
Tel: +44 (0) 7879 458 364 |
Tarquin Edwards |
[email protected] |
Notes for Editors
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.
The Company operates through the following divisional companies:
1. ValiFinn is the biomarkers and diagnostic development division
2. ValiPharma is the therapeutics division with two embedded technologies primarily directed at the treatment of cancers.
